Mutya Harsch - Jan 1, 2024 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
Chief Legal Officer and GC
Signature
/s/ Mutya Harsch
Stock symbol
VYNE
Transactions as of
Jan 1, 2024
Transactions value $
-$367
Form type
4
Date filed
1/3/2024, 05:20 PM
Previous filing
Dec 15, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Award $0 +62.5K +71.76% $0.00 150K Jan 1, 2024 Direct F1, F2
transaction VYNE Common Stock Tax liability -$367 -161 -0.11% $2.28 149K Jan 2, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNE Stock Option (right to buy) Award $0 +62.5K $0.00 62.5K Jan 1, 2024 Common Stock 62.5K $2.33 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F3 Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
F4 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.